Navigation Links
WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
Date:8/17/2008

PHILADELPHIA, Aug. 17 /Xinhua-PRNewswire/ -- WuXi AppTec, Inc., the operating company of WuXi PharmaTech (NYSE: WX) in the U.S., has announced the appointments of Garry Takle, Ph.D. as Vice President of Operations and Joseph Hughes, Ph.D. as Vice President of Testing Services for its Philadelphia facility.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Takle has been with the company for nine years in roles of increasing responsibility at the Philadelphia site, most recently as Vice President of R&D Testing. He has over 20 years' experience in the biopharm/biotech industry and previously worked at Wellcome (now GSK UK), the Rockefeller University and Innovir. Dr. Takle received his Ph.D. in Cellular Immunology from the University of Glasgow.

In his new position, Dr. Takle will focus on continuous improvements in operations at the Philadelphia facility and will have overall responsibility for biologics manufacturing services.

Dr. Hughes has been with the company for over 10 years in various leadership capacities. He has over 29 years' experience in the industry, including previous positions at Merck Sharp and Dohme Research Laboratories and at Sterling Winthrop. Dr. Hughes received his Ph.D. in Microbiology from Northwestern University.

In his new position, Dr. Hughes will take on direct management of all of the testing laboratories at the Philadelphia facility and also work to expand WuXi AppTec's biologics services and client base.

Both Dr. Takle and Dr. Hughes will report directly to Edward Hu, Chief Operating Officer of WuXi PharmaTech.

"Expanding my role at the WuXi AppTec Philadelphia site is an exciting opportunity," said Dr. Takle, "and I look forward to working with our excellent team on the continuing goal of making this facility the best in its class for outsourced process development and contract manufacturing."

"I am very excited to lead all the Philadelphia laboratories as we continue expansion of our capabilities and capacities to provide the biologics industry with the highest quality in testing services," said Dr. Hughes.

"WuXi AppTec is fortunate to have two such experienced and talented managers within our organization to tap for these important roles," said Mr. Hu. "Their deep understanding of the industry, their many years with the company and their proven track record as leaders will be tremendous assets as the Philadelphia facility continues to grow and strengthen its services for the biologics industry."

About WuXi AppTec, Inc.

WuXi AppTec, Inc. is the operating company of WuXi PharmaTech in the U.S. WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com.

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.co


'/>"/>
SOURCE WuXi AppTec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi AppTec VP and GM Invited to Join the AAMI Standards Board
2. WuXi PharmaTech Completes Acquisition of AppTec
3. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. RainDance Technologies Appoints Olex Vice President, System Development
6. Omeros Appoints David A. Mann to its Board of Directors
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
9. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
10. SAFC Appoints New Vice President of Quality and Regulatory Affairs
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... Mass. (PRWEB) , ... March 22, 2017 , ... ... scale up human tissue regeneration from small lab samples to full-size tissues, bones, ... how to establish a vascular system that delivers blood deep into the developing ...
Breaking Biology Technology:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):